Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

MedImmune LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1987-01-01

Employees: 5K

Market Cap: -

Website: http://medimmune.com

Clinical Trials

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer Squamous (NSCLC-Sq)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Small Cell Lung Cancer (SCLC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Colorectal Cancer (CRC)
Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: MEDI7247

First Posted Date: 2019-01-22

Last Posted Date: 2019-12-30

Lead Sponsor: MedImmune LLC

Target Recruit Count: 8

Registration Number: NCT03811652

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Resectable
Early-stage
NSCLC

Interventions: Drug: Durvalumab
Combination Product: Oleclumab
Combination Product: Monalizumab
Combination Product: Danvatirsen

First Posted Date: 2019-01-07

Last Posted Date: 2022-02-24

Lead Sponsor: MedImmune LLC

Target Recruit Count: 84

Registration Number: NCT03794544

Locations: 🇨🇭
Research Site, Zurich, Switzerland

A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: MEDI0382

First Posted Date: 2018-11-19

Last Posted Date: 2020-06-05

Lead Sponsor: MedImmune LLC

Target Recruit Count: 20

Registration Number: NCT03745937

Locations: 🇩🇪
Research Site, Neuss, Germany

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Atherosclerosis
Cardiovascular Disease

Interventions: Biological: MEDI6570
Biological: Part B Placebo
Biological: Placebo

First Posted Date: 2018-08-31

Last Posted Date: 2020-08-24

Lead Sponsor: MedImmune LLC

Target Recruit Count: 88

Registration Number: NCT03654313

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States

A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Placebo
Drug: MEDI0382

First Posted Date: 2018-08-10

Last Posted Date: 2021-08-23

Lead Sponsor: MedImmune LLC

Target Recruit Count: 51

Registration Number: NCT03625778

Locations: 🇺🇸
Research Site, Dallas, Texas, United States

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Phase 1

Completed

Conditions: Carcinoma
Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Oleclumab
Drug: Durvalumab
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Nab-paclitaxel
Drug: Folinic acid
Drug: 5-FU

First Posted Date: 2018-08-02

Last Posted Date: 2023-10-03

Lead Sponsor: MedImmune LLC

Target Recruit Count: 213

Registration Number: NCT03611556

Locations: 🇪🇸
Research Site, Pamplona, Spain

A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type II
Obesity

Interventions: Drug: MEDI0382
Drug: Placebo

First Posted Date: 2018-07-23

Last Posted Date: 2023-01-19

Lead Sponsor: MedImmune LLC

Target Recruit Count: 28

Registration Number: NCT03596177

Locations: 🇬🇧
Research Site, Cambridge, United Kingdom

A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction

Phase 2

Completed

Conditions: ST Elevation Myocardial Infarction

Interventions: Biological: MEDI6012
Other: Placebo

First Posted Date: 2018-07-06

Last Posted Date: 2022-02-09

Lead Sponsor: MedImmune LLC

Target Recruit Count: 593

Registration Number: NCT03578809

Locations: 🇬🇧
Research Site, Stevenage, United Kingdom

D2560C00015 FluMist Annual Safety Study 2018

Phase 4

Completed

Conditions: Influenza
Healthy

Interventions: Biological: Bivalent influenza vaccine
Other: Placebo

First Posted Date: 2018-06-20

Last Posted Date: 2019-12-26

Lead Sponsor: MedImmune LLC

Target Recruit Count: 300

Registration Number: NCT03564444

Locations: 🇺🇸
Research Site, Portland, Oregon, United States

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Liraglutide
Drug: MEDI0382

First Posted Date: 2018-06-14

Last Posted Date: 2024-11-11

Lead Sponsor: MedImmune LLC

Target Recruit Count: 51

Registration Number: NCT03555994

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy